<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527943</url>
  </required_header>
  <id_info>
    <org_study_id>P04736</org_study_id>
    <secondary_id>TRA•CER</secondary_id>
    <secondary_id>2006-002809-31</secondary_id>
    <secondary_id>MK-5348-014</secondary_id>
    <nct_id>NCT00527943</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to determine whether vorapaxar, when added to the existing standard of
      care (eg, aspirin, clopidogrel) for preventing heart attack and stroke in patients with acute
      coronary syndrome, will yield additional benefit over the existing standard of care in
      preventing heart attack and stroke.

      The study is also designed to assess risk of bleeding with vorapaxar added to the standard of
      care versus the standard of care alone.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was terminated at the request of the Data and Safety Monitoring Board.
  </why_stopped>
  <start_date type="Actual">December 1, 2007</start_date>
  <completion_date type="Actual">July 1, 2011</completion_date>
  <primary_completion_date type="Actual">July 1, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular Death, Myocardial Infarction, Stroke, Recurrent Ischemia With Re-hospitalization, and/or Urgent Coronary Revascularization Within 2 Years From Randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: cardiovascular (CV) death, myocardial infarction (MI), stroke, recurrent ischemia with re-hospitalization (RIR), and/or urgent coronary revascularization (UCR). A Clinical Endpoints Committee (CEC) reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced at least 1 of the components of the primary composite efficacy endpoint within 2 years from randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular Death, Myocardial Infarction, and/or Stroke Within 2 Years From Randomization</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: cardiovascular (CV) death, myocardial infarction (MI), and/or stroke. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced at least 1 of the components of the secondary composite efficacy endpoint within 2 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Met Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) Moderate or Severe Bleeding Criteria Within 2 Years From Randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Adverse events were categorized as &quot;bleeding events&quot; if the intensity of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the GUSTO cooperative group criteria as follows: Mild , Moderate or Severe and the grading was adjudicated by the CEC. The Kaplan-Meier estimate reports the percentage of participants who experienced GUSTO moderate or severe bleeding within 2 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Clinically Significant Bleeding Within 2 Years From Randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Adverse events were categorized as &quot;bleeding events&quot; if the intensity of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria as major, minor or other. &quot;Clinically Significant Bleeding&quot; was defined as the composite of TIMI Major bleeding, TIMI Minor bleeding, or bleeding that required unplanned medical or surgical treatment or unplanned laboratory evaluation even if it did not meet the criteria for TIMI major or minor bleeding. The Kaplan-Meier estimate reports the percentage of participants who experienced clinically significant bleeding within 2 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, or UCR Within 2 Years From Randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, or UCR within 2 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death or MI Within 2 Years From Randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death or MI. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death or MI within 2 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced All-cause Death, MI, Stroke, RIR, or UCR Within 2 Years From Randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: all-cause death, MI, stroke, RIR, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced all-cause death, MI, stroke, RIR, or UCR within 2 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced All-cause Death, MI, Stroke, or UCR Within 2 Years From Randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: all-cause death, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced all-cause Death, MI, stroke, or UCR I within 2 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death Within 2 Years From Randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time (in days) from study start to the CV death (if reported) was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death within 2 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced an MI Within 2 Years From Randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of an MI was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced an MI within 2 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced RIR Within 2 Years From Randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of RIR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced RIR within 2 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced UCR Within 2 Years From Randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of UCR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced UCR within 2 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause Within 2 Years From Randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time (in days) from study start to death from any cause was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause within 2 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced a Stroke Within 2 Years From Randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time (in days) from study start to first experience of a stroke was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced a stroke within 2 years from randomization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12944</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vorapaxar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorapaxar</intervention_name>
    <description>oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year</description>
    <arm_group_label>Vorapaxar</arm_group_label>
    <other_name>SCH 530348</other_name>
    <other_name>MK-5348</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men and women at least 18 years old with current clinical manifestation of
        non-ST-segment-elevation myocardial infarction (heart attack) according to the following
        three criteria:

          -  current symptoms of cardiac ischemia (chest pain leading to cardiac ischemia or heart
             attack)

        AND

          -  either of the following:

               -  concurrent elevation of troponin I or T, or of creatine kinase - myocardial band
                  (CK-MB) to a level above the upper limit of normal, OR

               -  concurrent appropriate electrocardiographic evidence

        AND

          -  any one (or more) of the following:

               -  age &gt;= 55 years

               -  documented history of prior heart attack or coronary revascularization (eg,
                  angioplasty [PCI], coronary artery replacement [CABG])

               -  diabetes (documented use of insulin or oral hypoglycemic[s])

               -  documented history of peripheral arterial disease

        Exclusion Criteria:

          -  history of intracranial hemorrhage or of central nervous system (CNS) surgery, tumor,
             or aneurysm

          -  any bleeding disorder or abnormality

          -  sustained severe hypertension or valvular heart disease

          -  current or recent platelet count &lt;100,000 mm^3

          -  planned or ongoing treatment with a blood thinning medication

          -  pregnancy

          -  any significant medical or physiological condition or abnormality that could put the
             subject at increased risk or limit the subject's ability to participate for the
             duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Storey RF, Kotha J, Smyth SS, Moliterno DJ, Rorick TL, Moccetti T, Valgimigli M, Dery JP, Cornel JH, Thomas GS, Huber K, Harrington RA, Hord E, Judge HM, Chen E, Strony J, Mahaffey KW, Tricoci P, Becker RC, Jennings LK. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost. 2014 May 5;111(5):883-91. doi: 10.1160/TH13-07-0624. Epub 2014 Jan 9.</citation>
    <PMID>24402559</PMID>
  </results_reference>
  <results_reference>
    <citation>Valgimigli M, Tricoci P, Huang Z, Aylward PE, Armstrong PW, Van de Werf F, Leonardi S, White HD, Widimsky P, Harrington RA, Cequier A, Chen E, Lokhnygina Y, Wallentin L, Strony J, Mahaffey KW, Moliterno DJ. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol. 2014 Sep 1;114(5):665-73. doi: 10.1016/j.amjcard.2014.05.054. Epub 2014 Jun 18.</citation>
    <PMID>25129064</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2007</study_first_submitted>
  <study_first_submitted_qc>September 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2007</study_first_posted>
  <results_first_submitted>May 9, 2014</results_first_submitted>
  <results_first_submitted_qc>May 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 9, 2014</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorapaxar</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=P04736&amp;kw=P04736&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Prior to the planned study completion, the Data Safety Monitoring Board recommended that all participants stop treatment and that the study be closed-out. The protocol-defined target number of primary efficacy endpoints had been reached by this time. However, follow-up in the study was terminated earlier than planned.</recruitment_details>
      <pre_assignment_details>The Intent to Treat (ITT) Population, defined as all enrolled participants who were randomly assigned to a treatment group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
        </group>
        <group group_id="P2">
          <title>Vorapaxar</title>
          <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6471"/>
                <participants group_id="P2" count="6473"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="6441"/>
                <participants group_id="P2" count="6446"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6311"/>
                <participants group_id="P2" count="6327"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
        </group>
        <group group_id="B2">
          <title>Vorapaxar</title>
          <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6471"/>
            <count group_id="B2" value="6473"/>
            <count group_id="B3" value="12944"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3369"/>
                    <measurement group_id="B2" value="3390"/>
                    <measurement group_id="B3" value="6759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 to &lt;75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2006"/>
                    <measurement group_id="B2" value="1973"/>
                    <measurement group_id="B3" value="3979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1096"/>
                    <measurement group_id="B2" value="1110"/>
                    <measurement group_id="B3" value="2206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1822"/>
                    <measurement group_id="B2" value="1810"/>
                    <measurement group_id="B3" value="3632"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4649"/>
                    <measurement group_id="B2" value="4663"/>
                    <measurement group_id="B3" value="9312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular Death, Myocardial Infarction, Stroke, Recurrent Ischemia With Re-hospitalization, and/or Urgent Coronary Revascularization Within 2 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: cardiovascular (CV) death, myocardial infarction (MI), stroke, recurrent ischemia with re-hospitalization (RIR), and/or urgent coronary revascularization (UCR). A Clinical Endpoints Committee (CEC) reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced at least 1 of the components of the primary composite efficacy endpoint within 2 years from randomization.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular Death, Myocardial Infarction, Stroke, Recurrent Ischemia With Re-hospitalization, and/or Urgent Coronary Revascularization Within 2 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: cardiovascular (CV) death, myocardial infarction (MI), stroke, recurrent ischemia with re-hospitalization (RIR), and/or urgent coronary revascularization (UCR). A Clinical Endpoints Committee (CEC) reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced at least 1 of the components of the primary composite efficacy endpoint within 2 years from randomization.</description>
          <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6471"/>
                <count group_id="O2" value="6473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9"/>
                    <measurement group_id="O2" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.072</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular Death, Myocardial Infarction, and/or Stroke Within 2 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: cardiovascular (CV) death, myocardial infarction (MI), and/or stroke. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced at least 1 of the components of the secondary composite efficacy endpoint within 2 years from randomization.</description>
        <time_frame>up to 2 years</time_frame>
        <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular Death, Myocardial Infarction, and/or Stroke Within 2 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: cardiovascular (CV) death, myocardial infarction (MI), and/or stroke. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced at least 1 of the components of the secondary composite efficacy endpoint within 2 years from randomization.</description>
          <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6471"/>
                <count group_id="O2" value="6473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Met Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) Moderate or Severe Bleeding Criteria Within 2 Years From Randomization</title>
        <description>Adverse events were categorized as “bleeding events” if the intensity of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the GUSTO cooperative group criteria as follows: Mild , Moderate or Severe and the grading was adjudicated by the CEC. The Kaplan-Meier estimate reports the percentage of participants who experienced GUSTO moderate or severe bleeding within 2 years from randomization.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>As Treated Population, which included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Met Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) Moderate or Severe Bleeding Criteria Within 2 Years From Randomization</title>
          <description>Adverse events were categorized as “bleeding events” if the intensity of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the GUSTO cooperative group criteria as follows: Mild , Moderate or Severe and the grading was adjudicated by the CEC. The Kaplan-Meier estimate reports the percentage of participants who experienced GUSTO moderate or severe bleeding within 2 years from randomization.</description>
          <population>As Treated Population, which included all participants who received at least 1 dose of study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6441"/>
                <count group_id="O2" value="6446"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Clinically Significant Bleeding Within 2 Years From Randomization</title>
        <description>Adverse events were categorized as “bleeding events” if the intensity of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria as major, minor or other. “Clinically Significant Bleeding” was defined as the composite of TIMI Major bleeding, TIMI Minor bleeding, or bleeding that required unplanned medical or surgical treatment or unplanned laboratory evaluation even if it did not meet the criteria for TIMI major or minor bleeding. The Kaplan-Meier estimate reports the percentage of participants who experienced clinically significant bleeding within 2 years from randomization.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>As Treated Population, which included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Clinically Significant Bleeding Within 2 Years From Randomization</title>
          <description>Adverse events were categorized as “bleeding events” if the intensity of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria as major, minor or other. “Clinically Significant Bleeding” was defined as the composite of TIMI Major bleeding, TIMI Minor bleeding, or bleeding that required unplanned medical or surgical treatment or unplanned laboratory evaluation even if it did not meet the criteria for TIMI major or minor bleeding. The Kaplan-Meier estimate reports the percentage of participants who experienced clinically significant bleeding within 2 years from randomization.</description>
          <population>As Treated Population, which included all participants who received at least 1 dose of study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6441"/>
                <count group_id="O2" value="6446"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, or UCR Within 2 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, or UCR within 2 years from randomization.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, or UCR Within 2 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, or UCR within 2 years from randomization.</description>
          <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6471"/>
                <count group_id="O2" value="6473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                    <measurement group_id="O2" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death or MI Within 2 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death or MI. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death or MI within 2 years from randomization.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death or MI Within 2 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death or MI. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death or MI within 2 years from randomization.</description>
          <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6471"/>
                <count group_id="O2" value="6473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                    <measurement group_id="O2" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced All-cause Death, MI, Stroke, RIR, or UCR Within 2 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: all-cause death, MI, stroke, RIR, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced all-cause death, MI, stroke, RIR, or UCR within 2 years from randomization.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Intent to Treat population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced All-cause Death, MI, Stroke, RIR, or UCR Within 2 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: all-cause death, MI, stroke, RIR, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced all-cause death, MI, stroke, RIR, or UCR within 2 years from randomization.</description>
          <population>Intent to Treat population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6471"/>
                <count group_id="O2" value="6473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                    <measurement group_id="O2" value="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.174</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced All-cause Death, MI, Stroke, or UCR Within 2 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: all-cause death, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced all-cause Death, MI, stroke, or UCR I within 2 years from randomization.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced All-cause Death, MI, Stroke, or UCR Within 2 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: all-cause death, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced all-cause Death, MI, stroke, or UCR I within 2 years from randomization.</description>
          <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6471"/>
                <count group_id="O2" value="6473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8"/>
                    <measurement group_id="O2" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death Within 2 Years From Randomization</title>
        <description>The time (in days) from study start to the CV death (if reported) was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death within 2 years from randomization.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death Within 2 Years From Randomization</title>
          <description>The time (in days) from study start to the CV death (if reported) was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death within 2 years from randomization.</description>
          <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6471"/>
                <count group_id="O2" value="6473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.963</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced an MI Within 2 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of an MI was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced an MI within 2 years from randomization.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced an MI Within 2 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of an MI was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced an MI within 2 years from randomization.</description>
          <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6471"/>
                <count group_id="O2" value="6473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced RIR Within 2 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of RIR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced RIR within 2 years from randomization.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced RIR Within 2 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of RIR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced RIR within 2 years from randomization.</description>
          <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6471"/>
                <count group_id="O2" value="6473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.418</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced UCR Within 2 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of UCR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced UCR within 2 years from randomization.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced UCR Within 2 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of UCR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced UCR within 2 years from randomization.</description>
          <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6471"/>
                <count group_id="O2" value="6473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.493</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause Within 2 Years From Randomization</title>
        <description>The time (in days) from study start to death from any cause was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause within 2 years from randomization.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause Within 2 Years From Randomization</title>
          <description>The time (in days) from study start to death from any cause was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause within 2 years from randomization.</description>
          <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6471"/>
                <count group_id="O2" value="6473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.515</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced a Stroke Within 2 Years From Randomization</title>
        <description>The time (in days) from study start to first experience of a stroke was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced a stroke within 2 years from randomization.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced a Stroke Within 2 Years From Randomization</title>
          <description>The time (in days) from study start to first experience of a stroke was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced a stroke within 2 years from randomization.</description>
          <population>Intent to Treat Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6471"/>
                <count group_id="O2" value="6473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.606</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events are reported using the As Treated Population, which included all participants who received at least 1 dose of study medication and are reported according to treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
        </group>
        <group group_id="E2">
          <title>Vorapaxar</title>
          <description>Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1718" subjects_at_risk="6441"/>
                <counts group_id="E2" subjects_affected="1866" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="6441"/>
                <counts group_id="E2" events="59" subjects_affected="55" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>EOSINOPHILIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GRANULOCYTOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC DIATHESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEPARIN-INDUCED THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPOCHROMIC ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>IDIOPATHIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY MEDIASTINAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MICROCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NORMOCHROMIC NORMOCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SPLENIC INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SPONTANEOUS HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="6441"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA SUPRAVENTRICULAR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTERIOSPASM CORONARY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="100" subjects_affected="93" subjects_at_risk="6441"/>
                <counts group_id="E2" events="113" subjects_affected="96" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="6441"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ATRIAL RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ATRIAL THROMBOSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR DISSOCIATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BIFASCICULAR BLOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BRADYARRHYTHMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="6441"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK LEFT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIAC ASTHMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="191" subjects_affected="146" subjects_at_risk="6441"/>
                <counts group_id="E2" events="191" subjects_affected="142" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="46" subjects_affected="35" subjects_at_risk="6441"/>
                <counts group_id="E2" events="53" subjects_affected="45" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIAC HYPERTROPHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIAC PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIAC TAMPONADE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIAC VALVE DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" events="41" subjects_affected="39" subjects_at_risk="6441"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIOMEGALY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHORDAE TENDINAE RUPTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COR PULMONALE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISSECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DRESSLER'S SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROCARDIAC SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEART VALVE CALCIFICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MYOCARDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MYOPERICARDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NODAL ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NODAL RHYTHM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PAPILLARY MUSCLE RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6441"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERICARDIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6441"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERICARDITIS CONSTRICTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PLEUROPERICARDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PRINZMETAL ANGINA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PULSELESS ELECTRICAL ACTIVITY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RESTRICTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6441"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SINOATRIAL BLOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SINUS ARREST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SINUS ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>STRESS CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6441"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TORSADE DE POINTES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TRICUSPID VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TRIFASCICULAR BLOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VENTRICLE RUPTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" events="33" subjects_affected="28" subjects_at_risk="6441"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="41" subjects_affected="36" subjects_at_risk="6441"/>
                <counts group_id="E2" events="29" subjects_affected="23" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIOVENOUS MALFORMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ATRIAL SEPTAL DEFECT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ANGIODYSPLASIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ANGIODYSPLASIA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ARTERIOVENOUS MALFORMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYDROCELE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PHIMOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>DEAFNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DEAFNESS NEUROSENSORY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>EAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUDDEN HEARING LOSS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VERTIGO POSITIONAL</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VESTIBULAR DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TOXIC NODULAR GOITRE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ABNORMAL SENSATION IN EYE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIPLOPIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>EYE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GLAUCOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MACULAR HOLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OPTIC ISCHAEMIC NEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RETINAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RETINAL VASCULAR THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>STRABISMUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ULCERATIVE KERATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VISUAL IMPAIRMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="6441"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ABDOMINAL STRANGULATED HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ACUTE ABDOMEN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ANAL FISTULA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ANAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COELIAC DISEASE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="6441"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIABETIC GASTROPARESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIARRHOEA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DUODENITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ENTEROVESICAL FISTULA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>EROSIVE OESOPHAGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FOOD POISONING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTRIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTRIC POLYPS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="6441"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTRIC VARICES HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTRITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTRODUODENITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL EROSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6441"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL NECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6441"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6441"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC EROSIVE GASTRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPERCHLORHYDRIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ILEUS PARALYTIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTESTINAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LOCALISED INTRAABDOMINAL FLUID COLLECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MECHANICAL ILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="6441"/>
                <counts group_id="E2" events="40" subjects_affected="38" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MESENTERIC VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PANCREATIC CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERIODONTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERITONEAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PHARYNGOESOPHAGEAL DIVERTICULUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="6441"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>REFLUX OESOPHAGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL FIBROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUBILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TONGUE DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLOODY DISCHARGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="6441"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="6441"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="42" subjects_affected="33" subjects_at_risk="6441"/>
                <counts group_id="E2" events="30" subjects_affected="29" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DEVICE BREAKAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DEVICE DISLOCATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DEVICE MALFUNCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DRUG INTOLERANCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>EXERCISE TOLERANCE DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GENERALISED OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPOTHERMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INFLAMMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INJECTION SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LOCAL SWELLING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6441"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="127" subjects_affected="112" subjects_at_risk="6441"/>
                <counts group_id="E2" events="158" subjects_affected="141" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POLYP</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PUNCTURE SITE REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SECRETION DISCHARGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SENSATION OF PRESSURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUDDEN CARDIAC DEATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BILE DUCT OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BILIARY DYSKINESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6441"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6441"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GALLBLADDER DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEPATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEPATITIS ACUTE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEPATITIS TOXIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGY TO CHEMICALS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>AMYLOIDOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ANTIPHOSPHOLIPID SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CONTRAST MEDIA ALLERGY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SARCOIDOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ABDOMINAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ABDOMINAL SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ABSCESS ORAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>APPENDICITIS PERFORATED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS GRAFT SITE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTERITIS INFECTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTHRITIS INFECTIVE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BORRELIA INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="6441"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BRONCHITIS VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="6441"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHEST WALL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS INFECTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="6441"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>EYE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="6441"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS NOROVIRUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS SALMONELLA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GRAFT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GROIN ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GROIN INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>H1N1 INFLUENZA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMATOMA INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEPATITIS B</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEPATITIS C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HERPES SIMPLEX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HIV INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INCISION SITE INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INFECTED CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INFECTED SEBACEOUS CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INFECTED SKIN ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISCITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LEISHMANIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LEPROSY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LIP INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION PSEUDOMONAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LYMPH NODE ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MEDIASTINITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MENINGITIS ASEPTIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>METAPNEUMOVIRUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NECROTISING FASCIITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NOCARDIOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ORCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6441"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS CHRONIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA CHRONIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PELVIC ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERICARDITIS TUBERCULOUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERIDIVERTICULAR ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERIRECTAL ABSCESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERITONEAL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="93" subjects_affected="83" subjects_at_risk="6441"/>
                <counts group_id="E2" events="111" subjects_affected="100" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PNEUMONIA HAEMOPHILUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PNEUMONIA INFLUENZAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PNEUMONIA KLEBSIELLA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PNEUMOCOCCAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PRIMARY ATYPICAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PSEUDOMEMBRANOUS COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PSEUDOMONAS BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PSOAS ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PYOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SCROTAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="6441"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="6441"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SERRATIA INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SHUNT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SIALOADENITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINE GANGRENE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL MEDIASTINITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>STERNITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>STITCH ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="6441"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VESTIBULAR NEURONITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="6441"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>WOUND SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ANAEMIA POSTOPERATIVE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTERIAL INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BACK INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIAC PROCEDURE COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIAC VALVE RUPTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE TRAUMATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COLLAPSE OF LUNG</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COMMINUTED FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CONFUSION POSTOPERATIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CRUSH INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>EXTRADURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FACE INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="6441"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FOREARM FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STOMA COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GUN SHOT WOUND</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEPATIC HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEPATIC RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INCISION SITE COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INCISION SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INFLAMMATION OF WOUND</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LIMB TRAUMATIC AMPUTATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MENISCUS LESION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MULTIPLE FRACTURES</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MUSCLE STRAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OPEN FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OPERATIVE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="6441"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PATELLA FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERIPROSTHETIC FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL DISCHARGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="91" subjects_affected="91" subjects_at_risk="6441"/>
                <counts group_id="E2" events="114" subjects_affected="112" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ILEUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE THORACIC PROCEDURE COMPLICATION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POSTPERICARDIOTOMY SYNDROME</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PUBIS FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SHUNT MALFUNCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SKULL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SKULL FRACTURED BASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SPLENIC RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>STAB WOUND</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>STERNAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TENDON INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TRANSPLANT FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TRAUMATIC LIVER INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TRAUMATIC LUNG INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION POSTOPERATIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VASCULAR PROCEDURE COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VASOPLEGIA SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VENA CAVA INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>WOUND COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>WOUND HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>WOUND SECRETION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLEEDING TIME PROLONGED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE MB INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLOOD CULTURE POSITIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIAC MONITORING ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CAROTID BRUIT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION DECREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QRS COMPLEX PROLONGED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6441"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEART RATE IRREGULAR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LIPOPROTEIN (A) INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OCCULT BLOOD POSITIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>URINE OUTPUT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>CACHEXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="6441"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ELECTROLYTE IMBALANCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FLUID RETENTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6441"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIC HYPEROSMOLAR NONKETOTIC SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6441"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIC UNCONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LACTIC ACIDOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTHRITIS REACTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTHROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTICULAR CALCIFICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6441"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CERVICAL SPINAL STENOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHONDRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COMPARTMENT SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CRYSTAL ARTHROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GROIN PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMARTHROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>JOINT EFFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>KYPHOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MUSCLE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MUSCLE TIGHTNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="6441"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MYALGIA INTERCOSTAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MYOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MYOSCLEROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="6441"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POLYARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SCOLIOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SPINAL DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SPONDYLOLISTHESIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SYMPATHETIC POSTERIOR CERVICAL SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SYNOVIAL CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TENDONITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TRIGGER FINGER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ADRENAL ADENOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ADRENAL NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BENIGN LUNG NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BENIGN NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BENIGN NEOPLASM OF BLADDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BENIGN OESOPHAGEAL NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BILE DUCT CANCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLADDER NEOPLASM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BLADDER TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BRAIN NEOPLASM BENIGN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BREAST NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BRONCHIAL CARCINOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CANCER PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARDIAC VALVE FIBROELASTOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMANGIOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHRONIC LYMPHOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHRONIC MYELOMONOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6441"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COLON CANCER STAGE II</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COLON CANCER STAGE III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COLON NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COLORECTAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER STAGE I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FIBROMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER STAGE 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTRIC NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL TRACT ADENOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HODGKIN'S DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HODGKIN'S DISEASE MIXED CELLULARITY STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTESTINAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTRAOCULAR MELANOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>IRITIC MELANOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LARGE CELL CARCINOMA OF THE RESPIRATORY TRACT STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LARYNGEAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LIPOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE III</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MALIGNANT GLIOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MEDIASTINUM NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>METASTASES TO BONE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>METASTASES TO CENTRAL NERVOUS SYSTEM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>METASTASES TO LARYNX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>METASTASES TO LIVER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>METASTASES TO LUNG</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>METASTASES TO LYMPH NODES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>METASTATIC MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>METASTATIC NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>METASTATIC RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>METASTATIC SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MYELODYSPLASTIC SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NASAL CAVITY CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NEUROENDOCRINE CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NON-SMALL CELL LUNG CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA RECURRENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OVARIAN NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PAGET'S DISEASE OF SKIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PAPILLOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PHAEOCHROMOCYTOMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PITUITARY TUMOUR BENIGN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER RECURRENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PROSTATIC ADENOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RECTAL ADENOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RECTAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RECTAL NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL CANCER</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL CANCER RECURRENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA RECURRENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL NEOPLASM</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL ONCOCYTOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SARCOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINE CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>T-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TESTIS CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>THYROID NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>UTERINE CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ALCOHOLIC SEIZURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ATAXIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BRACHIAL PLEXOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BRAIN MASS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BRAIN OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="6441"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CEREBELLAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CEREBRAL HYPOPERFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CERVICOBRACHIAL SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CLUSTER HEADACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6441"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CRANIAL NERVE PARALYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CRITICAL ILLNESS POLYNEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DEMENTIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DEMENTIA ALZHEIMER'S TYPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DEMENTIA WITH LEWY BODIES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIABETIC NEUROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DYSAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="6441"/>
                <counts group_id="E2" events="35" subjects_affected="33" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC STROKE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC TRANSFORMATION STROKE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HEPATIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPOKINESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPOTONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPOXIC-ISCHAEMIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTERCOSTAL NEURALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL ANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MENTAL IMPAIRMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MYASTHENIA GRAVIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MYELOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NERVE COMPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NERVE DEGENERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NERVE ROOT COMPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NEURITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NEUROMYOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NORMAL PRESSURE HYDROCEPHALUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PARAPARESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PARKINSON'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERONEAL NERVE PALSY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PHRENIC NERVE PARALYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PSYCHOMOTOR HYPERACTIVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SEDATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SENSORIMOTOR DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SENSORY LOSS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SPONDYLITIC MYELOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUBDURAL HYGROMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="6441"/>
                <counts group_id="E2" events="48" subjects_affected="44" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SYRINGOMYELIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VASCULAR ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VERTEBRAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VIITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ABNORMAL BEHAVIOUR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ADJUSTMENT DISORDER WITH MIXED DISTURBANCE OF EMOTION AND CONDUCT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ALCOHOL ABUSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ALCOHOL WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ALCOHOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ANXIETY DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BIPOLAR I DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="6441"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HALLUCINATION, VISUAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SCHIZOAFFECTIVE DISORDER BIPOLAR TYPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUBSTANCE ABUSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TOBACCO WITHDRAWAL SYMPTOMS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BLADDER DYSFUNCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CALCULUS BLADDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CALCULUS URINARY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="6441"/>
                <counts group_id="E2" events="37" subjects_affected="31" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE URINARY TRACT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NEPHROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NEPHROPATHY TOXIC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NEPHROTIC SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NEUROGENIC BLADDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE UROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POLYURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL ANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="55" subjects_affected="50" subjects_at_risk="6441"/>
                <counts group_id="E2" events="61" subjects_affected="56" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="38" subjects_affected="36" subjects_at_risk="6441"/>
                <counts group_id="E2" events="39" subjects_affected="38" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RENAL TUBULAR NECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>STRESS URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TUBULOINTERSTITIAL NEPHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>URINARY TRACT OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BREAST INFLAMMATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CYSTOCELE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>EPIDIDYMITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>GENITAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PELVIC FLUID COLLECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POSTMENOPAUSAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PROSTATITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PROSTATOMEGALY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RECTOCELE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>UTERINE ENLARGEMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>UTERINE PROLAPSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VAGINAL PROLAPSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6441"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="6441"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ALLERGIC GRANULOMATOUS ANGIITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ALVEOLITIS ALLERGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>APNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ASPIRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BRONCHIAL HYPERREACTIVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BRONCHIAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BRONCHITIS CHRONIC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="71" subjects_affected="51" subjects_at_risk="6441"/>
                <counts group_id="E2" events="68" subjects_affected="44" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CHYLOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIAPHRAGMATIC HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIAPHRAGMATIC PARALYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="6441"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DYSPNOEA PAROXYSMAL NOCTURNAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6441"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="6441"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMOTHORAX</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYDROTHORAX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPERVENTILATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LARYNGEAL OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LARYNGEAL STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NASAL POLYPS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE AIRWAYS DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL SWELLING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="31" subjects_affected="30" subjects_at_risk="6441"/>
                <counts group_id="E2" events="38" subjects_affected="32" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PLEURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PULMONARY ALVEOLAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="6441"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PULMONARY EOSINOPHILIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PULMONARY HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PULMONARY MASS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="6441"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="6441"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFLAMMATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RESTRICTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TONSILLAR HYPERTROPHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VOCAL CORD POLYP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DECUBITUS ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DERMATITIS EXFOLIATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIABETIC ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DYSHIDROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>NEUROPATHIC ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PEMPHIGOID</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PEMPHIGUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PURPURA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SKIN EXFOLIATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SKIN HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SKIN NECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>STASIS DERMATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS EMPHYSEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CARDIAC OPERATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CATARACT OPERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS MANAGEMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>WOUND DRAINAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ACCELERATED HYPERTENSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ANEURYSM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM RUPTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>AORTIC DISSECTION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>AORTIC DISSECTION RUPTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>AORTIC RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>AORTIC THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTERIAL STENOSIS LIMB</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS OBLITERANS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>COELIAC ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6441"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>DIABETIC MACROANGIOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ESSENTIAL HYPERTENSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY DISSECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6441"/>
                <counts group_id="E2" events="26" subjects_affected="20" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMODYNAMIC INSTABILITY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="6441"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="6441"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6441"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE EMERGENCY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="6441"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIC SHOCK</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ILIAC ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>INTRA-ABDOMINAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>JUGULAR VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LABILE HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>LERICHE SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>MALIGNANT HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6441"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PELVIC VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="6441"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY DISSECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERIPHERAL EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="6441"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="6441"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>POOR PERIPHERAL CIRCULATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SHOCK HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN STEAL SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>TEMPORAL ARTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>THROMBOANGIITIS OBLITERANS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS SUPERFICIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VARICOSE VEIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VASCULAR INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VASCULAR STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VASCULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VASODILATATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VENA CAVA THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6441"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="832" subjects_at_risk="6441"/>
                <counts group_id="E2" subjects_affected="1081" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="424" subjects_affected="385" subjects_at_risk="6441"/>
                <counts group_id="E2" events="451" subjects_affected="398" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="293" subjects_affected="228" subjects_at_risk="6441"/>
                <counts group_id="E2" events="552" subjects_affected="432" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="359" subjects_affected="310" subjects_at_risk="6441"/>
                <counts group_id="E2" events="399" subjects_affected="368" subjects_at_risk="6446"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All draft publications will be submitted to the Publication Committee for review. Full-length papers will be submitted at least 45 days prior to submission to a journal. Abstracts or public presentations (eg, poster) will be submitted at least 14 days in advance.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Prior to the planned study completion, the Data Safety Monitoring Board recommended that all participants stop treatment and that the study be closed-out. The protocol-defined target number of primary efficacy endpoints had been reached by this time.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

